Drug intelligence / Profile preview

Betasol

Development stage: Phase 2
Lead developer: Formosa Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Betasol is a brand name for a highly potent topical corticosteroid whose active ingredient is Clobetasol Propionate. It is a synthetic fluorinated glucocorticoid used for the treatment of various inflammatory and pruritic dermatological conditions. These conditions include frequently relapsing eczema, psoriasis, lichen planus, discoid lupus erythematosus, and dermatitis. Betasol works by reducing inflammation, redness, swelling, and itching associated with these skin disorders.

Brand names: Betasol

Targets

GR (Glucocorticoid receptor)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on Betasol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betasol.

Explore the full profile